Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability (2012 - 2026)

Jazz Pharmaceuticals has reported Non-Current Deferred Tax Liability for 15 years, with the latest figure at $547.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 18.35% year-over-year to $547.7 million; the trailing twelve-month figure through Mar 2026 stood at $547.7 million (down 18.35% YoY), and the FY2025 full-year result was $594.5 million, down 49.99% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $547.7 million, down from $594.5 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $1.4 billion in Q4 2023, with the low at $547.7 million in Q1 2026.
• Average Non-Current Deferred Tax Liability over 5 years is $879.8 million, with a median of $841.2 million recorded in 2023.
• Peak annual rise in Non-Current Deferred Tax Liability reached 1011.84% in 2022, while the deepest fall reached 50.37% in 2022.
• Tracing JAZZ's Non-Current Deferred Tax Liability over 5 years: stood at $944.3 million in 2022, then jumped by 46.73% to $1.4 billion in 2023, then declined by 14.2% to $1.2 billion in 2024, then plunged by 49.99% to $594.5 million in 2025, then fell by 7.87% to $547.7 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $547.7 million (Q1 2026), $594.5 million (Q4 2025), and $629.0 million (Q3 2025), per Business Quant data.

Peer Comparison